← Back to Screener
Barinthus Biotherapeutics plc American Depositary Shares (BRNS)
Price$0.65
Growth ScoreB
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-23.69%
Price vs S&P 500 (4W)-2.66%
VGM Score58.26
Market Capitalization$27.78M
All Metrics
Book Value / Share (Quarterly)$1.82
P/TBV (Annual)0.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)282.25%
Cash Flow / Share (Quarterly)$-1.18
Price vs S&P 500 (YTD)-14.82%
Net Profit Margin (TTM)-54.21%
EPS (TTM)$-1.12
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-1.12
Revenue Growth (5Y)16.92%
EPS (Annual)$-1.64
ROI (Annual)-89.52%
Net Profit Margin (5Y Avg)-5777.69%
Cash / Share (Quarterly)$1.72
ROA (Last FY)-67.67%
EBITD / Share (TTM)$-1.07
ROE (5Y Avg)-38.75%
Operating Margin (TTM)-62.66%
Cash Flow / Share (Annual)$-1.18
P/B Ratio0.42x
P/B Ratio (Quarterly)0.35x
Net Income / Employee (Annual)$-4,744,900
Net Interest Coverage (TTM)-15.07x
ROA (TTM)-38.90%
EPS Incl Extra (Annual)$-1.64
Current Ratio (Annual)7.76x
Quick Ratio (Quarterly)5.72x
3-Month Avg Trading Volume0.04M
52-Week Price Return-35.44%
EV / Free Cash Flow (Annual)-22.91x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.47
P/S Ratio (Annual)1.86x
Asset Turnover (Annual)0.09x
52-Week High$2.92
Operating Margin (5Y Avg)-6672.17%
EPS Excl Extra (Annual)$-1.64
CapEx CAGR (5Y)-33.75%
26-Week Price Return-15.76%
Quick Ratio (Annual)7.30x
13-Week Price Return8.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.05x
Enterprise Value$-38.08M
Revenue / Share Growth (5Y)13.60%
Asset Turnover (TTM)0.08x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-409.03%
Cash / Share (Annual)$1.72
3-Month Return Std Dev67.05%
Net Income / Employee (TTM)$-3,236,000
ROE (Last FY)-89.52%
EPS Basic Excl Extra (Annual)$-1.64
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.12
Receivables Turnover (Annual)0.27x
ROI (TTM)-49.57%
P/S Ratio (TTM)1.86x
Pretax Margin (5Y Avg)-5880.15%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.47
Price vs S&P 500 (52W)-59.80%
Year-to-Date Return-6.86%
5-Day Price Return-4.20%
EPS Normalized (Annual)$-1.64
ROA (5Y Avg)-31.22%
Net Profit Margin (Annual)-408.00%
Month-to-Date Return-4.20%
Cash Flow / Share (TTM)$-1.89
EBITD / Share (Annual)$-1.60
Operating Margin (Annual)-454.07%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-38.74%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.12
P/TBV (Quarterly)0.44x
P/B Ratio (Annual)0.37x
Pretax Margin (TTM)-54.33%
Book Value / Share (Annual)$1.82
Price vs S&P 500 (13W)0.43%
Beta-0.40x
Revenue / Share (TTM)$0.00
ROE (TTM)-49.57%
52-Week Low$0.51
gGradeB
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.14est. -0.29
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BRNSBarinthus Biotherapeutics plc American Depositary Shares | — | B | C | $0.65 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapies designed to treat chronic infectious diseases, autoimmune disorders, and cancer. The company operates a single business segment focused on the research and development of immunotherapies and vaccine candidates.